Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Effect of CDDO-2P-Im Treatment in Ovarian Cells

ABSTRACT: Effect of CDDO-2P-Im Treatment in Ovarian Cells

PROVIDER: PRJNA955225 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR24162905_1.fastq.gz	Fastqsanger.gz
	SRR24162905_2.fastq.gz	Fastqsanger.gz
	SRR24162906_1.fastq.gz	Fastqsanger.gz
	SRR24162906_2.fastq.gz	Fastqsanger.gz
	SRR24162907_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Effect of CDDO-2P-Im Treatment in Ovarian Cells

Project description:OVCAR-8 Cells were treated with various concentrations of CDDO-2P-Im for 6 hours and then RNA was extracted for gene expression changes

2023-04-20 | GSE229652 | GEO

Effect of CDDO-2P-Im Treatment in Myeloma Cells

Project description:RPMI8226 Cells were treated with various concentrations of CDDO-2P-Im for 6 hours and then RNA was extracted for gene expression changes

2023-03-19 | GSE221526 | GEO

Effect of CDDO-2P-Im Treatment in DIPG Cells

Project description:SF8628 Cells were treated with various concentrations of CDDO-2P-Im for 6 hours and then RNA was extracted for gene expression changes

2023-04-20 | GSE228434 | GEO

Effect of CDDO-2P-Im Treatment in Fibroblast Cells

Project description:Primary Dermal Fibroblasts (PDF) were treated with various concentrations of CDDO-2P-Im for 6 hours and then RNA was extracted for gene expression changes

2023-04-20 | GSE229704 | GEO

Effect of KEAP1 knockout and CDDO-2P-Im Treatment in ARH-77 Cells

Project description:ARH-77 cells were genetically editted with CRISPR-Cas9 to knock out KEAP1 and treated with various doses of CDDO-2P-Im or DMSO.

2023-04-20 | GSE229914 | GEO

Effect of CDDO-2P-Im Treatment in Myeloma Cells

Project description:Effect of CDDO-2P-Im Treatment in Myeloma Cells

| PRJNA914734 | ENA

Effect of CDDO-2P-Im Treatment in DIPG Cells

Project description:Effect of CDDO-2P-Im Treatment in DIPG Cells

| PRJNA949677 | ENA

Effect of CDDO-2P-Im Treatment in Fibroblast Cells

Project description:Effect of CDDO-2P-Im Treatment in Fibroblast Cells

| PRJNA955658 | ENA

The NRF2 inducer CDDO-2P-Im provokes a reduction in amyloid beta levels in Alzheimer’s disease model mice

Project description:Alzheimer’s disease (AD) is the most common etiology of dementia. The transcription factor NF-E2-related factor 2 (NRF2) induces the expression of genes encoding phase II detoxification and antioxidant genes. NRF2 is regulated by Kelch-like ECH-associated protein 1 (KEAP1), and the KEAP1-NRF2 system is the key regulatory system involved in cytoprotection. To examine whether pharmacological induction of NRF2 expression alleviates AD phenotypes in vivo, we employed two AD mouse models, i.e., AppNL-G-F/NL-G-F (AppNLGF) and APPV717I::TAUP301L (APP/TAU) mice. As the synthetic oleanane triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11-dien-28-oyl)] (CDDO)-4(-pyridin-2-yl)-imidazole (CDDO-2P-Im) exhibits strong NRF2-inducing activity, in this study, we treated AD model mice with CDDO-2P-Im.

2024-09-09 | GSE271154 | GEO

Effect of KEAP1 knockout and CDDO-2P-Im Treatment in ARH-77 Cells

Project description:Effect of KEAP1 knockout and CDDO-2P-Im Treatment in ARH-77 Cells

| PRJNA956574 | ENA